Simplexia - Chalmers Ventures
chalmers ventures portfolio company


Simplexia uses a new strategy to develop a vaccine against herpes simplex virus type 2 (HSV-2) infection. The vaccine is based on the HSV-2 type-specific glycoprotein G-2 (gG-2) and induces complete protection from disease in mice. The goal of the project is to conduct clinical I/II studies in humans.